Positive for Anaplastic Lymphoma Kinase (DBCOND0050986)

Identifiers

Synonyms

Anaplastic lymphoma kinase gene mutation / Anaplastic Lymphoma Kinase-positive

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02727335	Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements	No drug interventions	Not Available	Not Available	completed
NCT05525338	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels	Alectinib	treatment	4	recruiting
NCT01284192	Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)	ASP-3026	treatment	1	completed
NCT03546894	A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors	Alectinib Brigatinib Ceritinib Lorlatinib	Not Available	Not Available	completed